NCT05161845View on ClinicalTrials.gov

Clinical Trial of Measles, Mumps and Rubella Combined Vaccine, Live

PHASE4CompletedINTERVENTIONAL

Enrollment

1,068

Participants

Timeline

Start Date

December 23, 2021

Primary Completion Date

April 4, 2022

Study Completion Date

October 1, 2022

Conditions

ImmunotoxicityVaccine

Interventions

BIOLOGICAL

Measles, Mumps and Rubella Combined Vaccine, Live

0.5ml of reconstituted vaccine per container. 0.5 ml per single human dose containing not less than 3.0 lg CCID50 of both live measles virus and rubella virus and 4.3 lg CCID50 of live mumps virus.

Trial Locations (1)

Unknown

Jiangsu Provincial Center for Disease Control and Prevention, Nanjing

All Listed Sponsors

lead

Shanghai Institute Of Biological Products

INDUSTRY

NCT05161845 - Clinical Trial of Measles, Mumps and Rubella Combined Vaccine, Live | Biotech Hunter | Biotech Hunter